Table 1.

PI3-K/Akt/mTOR Inhibitors in Clinical Development

Agent	Company	Stage of Clinical Development
Pan-Isoform PI3-K Inhibitors
SAR245408 (XL147)	Sanofi/Adventis, Exelixis	Phase I, II
BKM120	Novartis	Phase II, III
GDC-0941	Genentech	Phase I, II
BAY 80–6946	Bayer	Phase I
GSK1059615	GlaxoSmithKline	Phase I
ZSTK474	Zenyaku	Phase I
PI3-K/mTOR Inhibitors
SAR254409 (XL765)	Sanofi/Adventis, Exelixis	Phase I, II
BEZ235	Novartis	Phase I, II
GDC-0980	Genentech	Phase I, II
GSK1059615	GlaxoSmithKline	Phase I
PF-04691502	Pfizer	Phase I
PKI-587	Pfizer	Phase I
PWT33597	Pathway Therapeutics	Phase I
Active Site mTOR Inhibitors
MLN0128	Millenium, Intellikine	Phase I
OSI-027	Astellas	Phase I
AZD8055	AstraZeneca	Phase I
Isoform-Specific PI3-K Inhibitors
BYL719 (alpha specific)	Novartis	Phase I
INK1117 (alpha specific	Intellikine/Millenium	Phase I
SAR260301 (beta specific)	Sanofi-Adventis	Phase I
TGR-1202 (delta specific)	TG Therapeutics	Phase I
GS-1101 (delta specific)	Gilead	Phase II-III
AS-252424 (upsilon specific)	Merck Serono	Pre-clinical
Akt Inhibitors
GDC-0068	Genentech	Phase I, II
MK2206 (allosteric inhibitor)	Merck	Phase I, II
GSK690693	GlaxoSmithKline	Phase I, II